• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Anticoagulation Management in the Perioperative Phase of Implantable Cardioverter Defibrillator Implantation
【24h】

Anticoagulation Management in the Perioperative Phase of Implantable Cardioverter Defibrillator Implantation

机译：植入式心脏复律除颤器植入术围手术期的抗凝管理

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: ?According to the current guidelines, substitution of warfarin with heparin is recommended as perioperative management in patients with high risk of thromboembolism. Optimal management of oral anticoagulation in patients undergoing implantable cardioverter defibrillator (ICD) implantation, however, remains controversial. Methods and Results: ?Bleeding complications among 273 consecutive patients undergoing initial ICD implantation were retrospectively analyzed. Patients were grouped according to medication at the time of device implantation: neither antiplatelet nor anticoagulation (N group, n=121); antiplatelet only (AP group, n=59); warfarin (W group, n=59); and heparin bridging (H group, n=34). The rate of the major bleeding complications, defined as hematoma requiring reoperation, cardiac tamponade, and pericardial effusion requiring additional hospital stay, was 1.7% in the N group, 0% in the AP group, 5.1% in the W group, and 17.6% in the H group (P
机译：背景：根据目前的指南，对于血栓栓塞风险高的患者，围术期建议使用肝素替代华法林。然而，对于植入式心脏复律除颤器（ICD）植入患者的口服抗凝药物的最佳管理仍存在争议。方法和结果：回顾性分析了273例接受ICD初始植入的患者的出血并发症。患者在装置植入时根据药物分组：既没有抗血小板也没有抗凝治疗（N组，n = 121）。仅抗血小板药（AP组，n = 59）;华法林（W组，n = 59）;肝素桥接（H组，n = 34）。 N组主要出血并发症的发生率定义为需要再次手术的血肿，心脏压塞和需要额外住院的心包积液，分别为1.7％，AP组为0％，W组为5.1％和17.6％。在H组（P

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号